Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share

  • Report ID: 6740
  • Published Date: Nov 26, 2024
  • Report Format: PDF, PPT

Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market

  1. Introduction
    1. Study Objective
    2. Scope of the report
    3. Market Taxonomy
  2. Study Assumptions and Abbreviations
    1. Research Methodology
    2. Secondary Research
    3. Primary Research
    4. SPSS Approach
    5. Data Triangulation
  3. Executive Summary
  4. Global Industry Overview  
    1. Market Overview
    2. Regional Synopsis
    3. Industry Supply Chain Analysis
    4. DROT
      1. Driver
      2. Restraint
      3. Opportunities
      4. Trends
    5. Government Regulation: How they would Aid the Business?
    6. Competitive Landscape
      1. AstraZeneca PLC
      2. Eli Lilly & Company
      3. Galmed Pharmaceuticals Ltd.
      4. GENFIT S.A.
      5. Novo Nordisk A/S
      6. Novartis AG
      7. PFIZER INC.
      8. Siemens Healthineers AG
      9. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      10. Zydus Lifesciences Limited
    7. SWOT Analysis
    8. Comparative Analysis Of The Current Technologies
    9. Company Share in The Market
    10. Analysis of Strategic Initiatives Adopted by Key Players
    11. Drug Type Analysis
    12. Growth Forecast of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
    13. Patent Analysis
    14. Recent Developments
    15. Industry Risk Assessment
  5. Global Outlook and Projections
    1. Global Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
      3. Year-on-Year Growth Forecast (%)
    2. Global Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
    3. Regional Synopsis (USD Million), 2024-2037
      1. North America, Value (USD Million)
      2. Europe, Value (USD Million)
      3. Asia Pacific, Value (USD Million)
      4. Latin America, Value (USD Million)
      5. Middle East and Africa, Value (USD Million)
  6. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  7. North America Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. U.S.
        2. Canada
    3. Cross Analysis of Drug Type W.R.T. End user  (USD Million), 2024-2037
  8. Europe Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. NORDIC
        7. Russia
        8. Rest of Europe
    3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  9. Asia Pacific Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. China
        2. Japan
        3. India
        4. Australia
        5. South Korea
        6. Vietnam
        7. Thailand
        8. Singapore
        9. Malaysia
        10. Rest of Asia Pacific
    3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  10. Latin America Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
    3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  11. Middle East & Africa Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
    3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  12. Global Economic Scenario
    1. World Economic Outlook
  13. About Research Nester
    1. Our Global Clientele
    2. We Serve Clients Across World

 


Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share

North America Market Analysis

North America non-alcoholic steatohepatitis therapeutics and diagnostics market is set to hold revenue share of over 36.8% by the end of 2037. The dominance of the region is attributed to the advanced healthcare infrastructure, a high prevalence rate of obesity and diabetes, and significant R&D investments by pharmaceutical companies. The U.S. and Canada are two leading markets in North America. Strong research institutions and supporting regulatory environments enhance the market potential of this region.

The U.S. is leading the non-alcoholic steatohepatitis therapeutics and diagnostics market due to the high prevalence of obesity and type 2 diabetes, which are two major risk factors for NAFLD/NASH. In addition, other ongoing drug development advances, such as the emergence of combination therapies, are being made to take care of unmet medical needs for a growing patient population. In March 2024, Max Biopharma and Metaba announced a collaboration on metabolomics studies to explore novel biomarkers and therapeutic targets for metabolic diseases, including NASH. Such partnerships aim to enhance the understanding of disease mechanisms and support the development of targeted treatments.  

The non-alcoholic steatohepatitis therapeutics and diagnostics market in Canada is also steadily growing, along with increased awareness and investments in healthcare infrastructure. An increasing trend toward the integration of lifestyle management programs with pharmaceutical interventions reflects a holistic approach to addressing NASH. Government activities aimed at liver health and diseases associated with obesity also create a favorable climate for trying new methods of treatment. Furthermore, new diagnostic technologies are being presented to the market that are likely to enable better identification of patients and improve outcomes of treatment.

Asia Pacific Market Statistics

Asia Pacific non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is predicted to grow at CAGR of over 28.8% through 2037, due to better access to healthcare, rising awareness, and proactively conducted screening programs. This growth is further supported by government programs regarding liver health and addressing non-communicable diseases. The large population base of the region and the growing burden of lifestyle-related diseases underpin its significant growth potential in the market.

India is anticipated to record considerable growth in the non-alcoholic steatohepatitis therapeutics and diagnostics market due to growing obesity, diabetes, and sedentary lifestyles among the population. Moreover, the increasing pharmaceutical industry in India facilitates cost-effective production with the distribution of therapeutics at economical rates, hence making treatments more accessible. For example, in July 2022, SRL Diagnostics launched the Fatty Liver Index test in India, which is a big leap toward early identification and management of liver disorders. Such innovations, along with rising efforts taken by the government to take control of metabolic disorders, are projected to drive market expansion.

The non-alcoholic steatohepatitis therapeutics and diagnostics market is expanding at a rapid pace in China due to increasing rates of obesity and diabetes in the country. The government's focus on improving access to healthcare and addressing chronic diseases should fuel further adoption of innovative therapies. Furthermore, partnerships among domestic pharmaceutical firms and international players promote drug development and NASH therapeutics and diagnostics market access. With significant investments in non-invasive diagnostic technologies, China is working to overcome the hurdles to early detection and treatment. As the country has a large pool of patients and increasing healthcare expenditure, there are several opportunities for players to expand.

Research Nester
Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Size
Get more information on this report: Request Free Sample PDF


Author Credits:  Radhika Pawar


  • Report ID: 6740
  • Published Date: Nov 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In 2024, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics was USD 4.6 billion.

The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market size was USD 4.6 billion in 2024 and is projected to reach USD 117 billion by the end of 2037, expanding at a CAGR of 28.1% during the forecast period, i.e., 2025-2037. In 2025, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics will be valued at USD 5.9 billion.

Key players in the market are AstraZeneca PLC, Eli Lilly & Company, Galmed Pharmaceuticals Ltd., Pfizer Inc., Genfit SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd., and Arcturus Therapeutics Inc among others.

The retail and specialty pharmacies segment is anticipated to lead the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.

North America is anticipated to offer lucrative prospects to companies in the non-alcoholic steatohepatitis (Nash) therapeutics and diagnostics market during the forecast period.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample